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Deciphering the molecular underpinnings of a disease is often only the first step toward developing
an effective treatment. The path from target identification to a successful therapeutic can be filled
with numerous hurdles that call for creative strategies. This Select highlights recent advances in
using gene therapy and engineered cells to treat cancers and chronic heart disease. Their success
in preliminary trials suggests that these unconventional strategies are close to becoming main-
stream options for refractory diseases.Bispecific T cells are created by the
introduction of genes that encode
the heterodimeric T cell receptor
(top) or chimeric antigen receptors
(CARs) that target surface antigens
in an MHC-independent fashion
(bottom) (LAT, linker for activation
of T cells; ScFv, single-chain vari-
able fragment; ZAP70, zeta chain-
associated protein kinase 70 kDa).
Image courtesy of C. June.Reengineering T Cells for Remission
For many patients with advanced chronic lymphocytic leukemia (CLL), the most common form
of leukemia in adults, a bonemarrow transplant is the best hope for long-term remission and the
only known cure. Now, in a new pilot clinical trial, Porter et al. and Kalos et al. achieve remission
of CLL by engineering patients’ own T cells to target leukemia cells.
CLL affects an individual’s B cells but leaves other arms of the immune system intact,
including T cells. Previous therapeutic attempts to harness the power of healthy T cells to fight
cancer havemet with variable success. To overcome these hurdles, Porter et al. and Kalos et al.
genetically modify the patient’s T cells to express a chimeric receptor with the antigen recog-
nition domain of an antibody fused to intracellular T cell activation domains (CD3-z) and
a T cell-specific costimulatory domain (CD137). The authors chose to target CD19 because it
is expressed only on malignant B cells, normal B cells, and B cell precursors. These engineered
T cells activate and expand in vivo, targeting cells expressing the specific antigen in an HLA-
independent manner.
Porter et al. and Kalos et al. observe antileukemic activity in all three of the patients who
receive the modified T cells, and after a month, two of the patients showed no evidence of
CLL in the bonemarrow. Both of these patients remain in remission beyond a year from therapy.
The T cells surprisingly persist in the patients as memory T cells, suggesting that, if the malig-
nant B cells return, the immune system will be ready to mount another antileukemic attack.
However, this also means that T cells will continue targeting healthy B cells, resulting in long-
term B cell deficiency, which is a clinically manageable problem. Although much work remains
in tempering the power of these engineered T cells, their therapeutic potential in B cell malig-
nancies is clear.
Porter, D., et al. (2011). N. Eng. J. Med. 365, 725–733.
Kalos, M., et al. (2011). Sci. Transl. Med. 3, 95ra7.Luciferase imaging of mice after tail
vein injection with DNA plasmid
liposomes demonstrates that the
engineered vector (VISA-claudin4-
Luc) is selectively expressed in
tumor, but not in normal, tissues,
whereas anonspecific vector (CMV-
Luc) was primarily expressed in
normal lung, the first targeting
tissue after tail vein injection.Removing Breast Cancer’s Roots
Cancer stem cells or cancer-initiating cells are a major therapeutic barrier because they have
the potential to initiate tumor growth with only a small population of cells. Although some cancer
therapies can stabilize the growth of this unique population, these cells are highly resistant to
apoptosis induced by both chemo- and radiotherapy. Now, Lang et al. present a new strategy
for killing these cells and for increasing their susceptibility to chemotherapy, thus lowering the
chance that the tumor will return.
Current chemotherapies for breast cancer disrupt pathways needed for cancer growth, result-
ing in apoptosis of cancer cells. It is thought that breast cancer-initiating cells evade these types
of treatment because they overexpress antiapoptotic proteins. Lang et al. demonstrate that
expression of a constitutively active mutant of the proapoptotic protein Bik (BikDD) can over-
come the protective effect of the antiapoptotic proteins. To target BikDD to breast cancer cells,
Lang et al. identify a promoter that is highly expressed in breast cancer using published expres-
sion data. They also take advantage of an innovative gene therapy vector that increases and
sustains transgene expression in cancer cells, selectively expressing BikDD at high levels
both in cells and in mice with virtually no toxicity.
Although BikDD expression potently kills breast cancer-initiating cells on its own, this therapy
is even more effective when used in combination with small-molecule chemotherapeutics. This
synergistic activity reduces the growth rate of tumors in xenograft mouse models even weeks
after cessation of therapy. These data suggest a promising strategy to eliminate breast cancer-
initiating cells with few side effects, even in patients whose previous cancer treatments were
unsuccessful.
Lang, J-Y., et al. (2011). Cancer Cell 20, 341–356.Cell 147, October 14, 2011 ª2011 Elsevier Inc. 253
Representative echocardiographic
images of a control and S100A1-treated
pig heart demonstrate that S100A1 effec-
tively prevents and reverses left ventric-
ular dysfunction 3 months after cardiac-
targeted intravenous gene therapy.
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for Molecular and Translational Cardi-
ology, Department of Medicine III, Hei-
delberg University, Germany.Help for Ailing Hearts
In patients with heart failure, the heart cannot pump enough blood throughout the body.
The heart attempts to compensate for its inefficiency, leading to a progressive loss of
myocardial tissue and numerous physiological changes. Most conventional therapies treat
a patient’s symptoms and help ameliorate disease, but they fail to reverse the progression
of the disease. Now, Pleger et al. take a step closer to treating the causes of progressive
heart failure with gene therapy. The authors demonstrate the safety and efficacy of using an
adenoviral vector to deliver the Ca2+ sensor protein, S100A1, in a pig model of chronic
heart failure.
Previous results from gene therapy trials in rodents suggested that this method may be
successful at restoring long-term cardiac function. However, given the differences
between mice and humans in anatomy, physiology, and cardiac output, it was hard to
assume that this therapy would be as effective in humans. Large animal models like the
pig approximate the human cardiovascular system more closely, and they are critical for
translating cardiac gene therapy to the clinic.
Pleger et al. experimentally trigger a myocardial infarction in the pigs, leading them to
develop heart failure within weeks. They then demonstrate that a minimally invasive
delivery system via a catheter can deliver therapeutically effective levels of engineered
adeno-associated virus directly to the heart. To help ensure targeted expression in the
heart, they place S100A1 under the control of a cardiomyocyte-specific promoter. Withinmonths after infusionwith the virus, expression of S100A1 rescues cardiac function, reverses cardiac enlargement, and restores Ca2+
handling. Based on these data, gene therapy with S100A1 may move into clinical trials in patients with heart failure and hopefully
reverse and prevent progression of this relentless disease.
Pleger, S., et al. (2011). Sci. Transl. Med. 3, 92ra64.Immunohistochemical staining for
vaccinia in biopsy of patient with meta-
static colorectal cancer 10 days follow-
ing viral (JX-594) infusion demonstrates
selective infection of tumor cells. Image
courtesy of Caroline Breitbach andDavid
Kirn.Poxvirus Poisons Cancers
Killing cancer cells with biological molecules, such as peptides, recombinant proteins, or
small interfering RNAs, is an attractive therapeutic strategy because these molecules can
potentially target pathways that small molecules cannot. However, treating solid tumors
with molecules is effective only when they can be delivered efficiently and specifically to
cancer tissues. Now, Breitbach et al. design an oncolytic poxvirus to express transgenes
selectively in the solid tumors of patients. The idea is to exploit the natural ability of a virus
to lyse and kill cells in which it replicates. Although simple in theory, achieving this requires
innovative approaches.
Breitbach et al. use vaccinia virus (a poxvirus used in smallpox vaccines), as this envel-
oped virus is known for its ability to evade recognition by the immune system, traffic readily
in the vasculature, and gain entry into a variety of cell types. To help the virus kill the tumor
cells, the authors engineer it to express a cytokine, GM-CSF, that stimulates the immune
system. The virus also decreases the tumor’s blood supply. The key to ensuring that the
virus replicates specifically inside of cancer cells is to delete the virus’s thymidine kinase
gene. This makes the virus dependent on the cell’s supply of thymidine kinase, a down-
stream target of the EGFR/Ras pathway, which is overexpressed in cancer cells.
Breitbach and colleagues then test the therapy on 23 patients with nine different types of
metastatic solid tumors refractory to conventional therapies. The patients receive a single
intravenous injection of the engineered virus, which displays minimal toxicity regardless of
the dose. The patients exhibit dose-dependent viral infectivity of the solid tumors, cancer
cell-specific viral replication and transgene expression, and corresponding antitumor
activity. Although the therapy is still in development (phase 2b), the broad potential of
this strategy is clear. These poxviruses can be modified to express any transgene or short
hairpin RNA that could promote tumor killing, making these viruses an ideal platform for
future therapies.
Breitbach, C., et al. (2011). Nature 477, 99–104.Cell 147, October 14, 2011 ª2011 Elsevier Inc. 255
